Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 72NIH 9INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 35Lymphoma, Follicular 31Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Pancreatic Neoplasms 15Neoplasm Metastasis 15Leukemia 15Squamous Cell Carcinoma of Head and Neck 12Melanoma 12Stomach Neoplasms 11Colorectal Neoplasms 11Prostatic Neoplasms 10Lymphoma, B-Cell, Marginal Zone 10Head and Neck Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

Imatinib Mesylate 15Dasatinib 14nilotinib 8olverembatinib 4asciminib 4ponatinib 3Cyclosporine 3bosutinib 2Methotrexate 2Homoharringtonine 2Cyclophosphamide 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2inecalcitol 1flumatinib 1fludarabine phosphate 1elsulfavirine 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1PF-114 1Mycophenolic Acid 1Interferon-alpha 1Hydroxyurea 1Fentanyl 1Everolimus 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Chronic-Phase × Cyclophosphamide × Clear all
NCT01175785 2019-03-05

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Nohla Therapeutics, Inc.

Phase 2 Completed
15 enrolled
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡